Gemcitabine from Actavis launched on patent expiry in EU markets

Gemcitabine from Actavis launched on patent expiry in EU markets

London, UK, 9 March 2009 - The oncology product Gemcitabine, produced by Actavis Group, the international generic pharmaceuticals company, was launched in EU markets, at patent expiry. The launch represents a significant milestone in Actavis' developing hospital business.

Gemcitabine is the first major oncology product to be made available by Actavis on the date of patent expiry in Western Europe.

Actavis will be manufacturing the Gemcitabine product at two of its manufacturing sites. Coupled with three registered sources for APIs (Active Pharmaceutical Ingredients), this will ensure one of the most robust and competitive supply chains in the industry. In March, Gemcitabine will be launched in Germany, France and the UK. The product will be launched in other five EU markets as tender cycles permit later in the year. The product has also previously been launched in several less regulated markets around the world.

"The day one launch of Gemcitabine is a great achievement for Actavis' hospital business, which was formed just over two years ago. This launch demonstrates our ability to compete in the demanding generic oncology arena. We will be selling this product alongside our growing range of other injectable generic products via our own hospital sales teams around the world and via select partners and distributors in various countries", said Scott Richards, EVP of Actavis' Hospital Business, speaking about the event.

The originator product, Lilly's Gemzar, is estimated to have generated around US$ 1.5 billion in annual revenue. Gemcitabine is used in the treatment of cancer including breast cancer, pancreatic cancer, bladder cancer and lung cancer.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.